Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jun 14;16(9):1819–1830. doi: 10.1158/1535-7163.MCT-17-0013

Figure 2. Nano-Orlistat decreases IC50 of taxanes in taxane-resistant prostate cancer cells.

Figure 2

Parent PC3 and DU145 or taxane-resistant PC3-TxR and DU145-TxR cells were treated with combinations of 8 concentrations of (A) paclitaxel, (B) docetaxel, and (C) cabazitaxel with 7 concentrations of NanoOrl. N = 6 replicates per combination. After 72 h, cell viability was assessed with the CCK-8 assay. Each dot represents the calculated IC50 value of the indicated taxane as a function of NanoOrl concentration, with the error bars representing the 95% confidence interval. Some error bars are not visible due to the small range of 95% confidence interval.